Biopharma

Product-based investments in late-stage clinical and commercial biopharmaceutical programs

PRODUCT FINANCE™ investing was developed by NovaQuest’s founders over 20 years ago as a tailored capital solution to support pivotal clinical trials and product launches, typically deployed through a nondilutive and noncontrolling investment structure. We are passionate about funding innovation in biopharmaceutical development. Better solutions for patients equal a healthier, more productive society.

By The Numbers

  • $2.5+ billion in total commitments
  • 10+ years of Biopharma investment experience
  • 35+ investments
  • 90% positive Phase III clinical trial success rate*

Investment Criteria

NovaQuest works directly with companies to help make their R&D pipelines a reality for patients and caregivers around the globe. We look to partner with seasoned teams of pharma operators focused on long term value creation, which have promising late-stage assets and unmet capital needs.

Intermediaries

We are open to collaboration with investment bankers, advisors, and intermediaries. Contact BD@nqcapital.com with opportunities and inquiries.

Transactions

Structure finance investments of $30-100 million of non-dilutive capital for the development and commercialization of late-stage pharmaceutical products.

Value-added Capital

We believe in value creation through partnership. NovaQuest provides capital, but also offers pharma operators the benefit of 300+ years of collective interdisciplinary biopharma experience to help realize value in their pipelines and grow their companies.

*As of December 31, 2021

See Our Product Finance Investments

Learn More

The information being provided is strictly as a courtesy. When you link to any of the websites provided here, you are leaving this website. We make no representation as to the completeness or accuracy of information provided at these websites, nor do we assume any risk of using such websites.

Proceed to Link